Related Experiment Video

Updated: Jun 22, 2025

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

12.2K

Dexamethasone-Induced Insulin Resistance Attenuation by Oral Sulfur-Oxidovanadium(IV) Complex Treatment in Mice

Eucilene K Batista1, Lidiane M A de Lima2, Dayane A Gomes1

  • 1Departamento de Fisiologia e Farmacologia, Centro de Biociências, Universidade Federal de Pernambuco, Recife 50670-901, PE, Brazil.

Pharmaceuticals (Basel, Switzerland)
|June 27, 2024
PubMed

Insights

This study shows that the oxidovanadium(IV) compound [VIVO(octd)] effectively lowers blood glucose and insulin resistance in mice. It offers a promising therapeutic for diabetes, even when complicated by glucocorticoid-induced insulin resistance.

Area of Science:

  • Inorganic Chemistry
  • Biochemistry
  • Pharmacology

Background:

  • Vanadium compounds exhibit insulin-enhancing and anti-diabetic properties.
  • Insulin resistance (IR) is a key factor in diabetes development and progression.
  • Glucocorticoids can induce or exacerbate insulin resistance.

Purpose of the Study:

  • To investigate the anti-diabetic effects of the oxidovanadium(IV) compound [VIVO(octd)] in a mouse model of glucocorticoid-induced insulin resistance.
  • To evaluate the compound's impact on key metabolic and oxidative stress markers.
  • To compare its efficacy against metformin.

Main Methods:

  • Characterization of [VIVO(octd)] using spectroscopic techniques (51V NMR, FTIR, EPR, UV-Vis, ESI-FT-MS).
  • Induction of insulin resistance in female Swiss mice using dexamethasone.
  • Oral administration of [VIVO(octd)] and metformin.
  • Assessment of hematological parameters, TyG index, hepatic lipids, glycogen, oxidative stress, and oral glucose tolerance tests.

Main Results:

  • [VIVO(octd)] demonstrated significant antioxidant effects.
  • Oral treatment (50 mg/kg) reduced fasting blood glucose by 50% (p < 0.05) and the TyG index by 25% (p < 0.05) compared to controls.
  • The compound showed comparable or beneficial effects to metformin in certain assays.

Conclusions:

  • The oxidovanadium-sulfur compound [VIVO(octd)] is a potent antihyperglycemic agent.
  • It is effective in managing diabetes, particularly in cases of glucocorticoid-induced insulin resistance.
  • This compound represents a promising therapeutic candidate for type 2 diabetes treatment.
Keywords:
diabetes mellitusinsulin resistancevanadium complex

More Related Videos

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

68.2K
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

94.4K

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
188
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
165
Oral Hypoglycemic Agents: &#945;-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
169
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
180